Internal Reference Number: FOI_7412
Date Request Received: 07/09/2023 00:00:00
Date Request Replied To: 29/09/2023 00:00:00
This response was sent via: By Email
Request Summary: Usage of biologic and biosimilar products by Rheumatology Department
Request Category: Companies
| Question Number 1: Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs: • Abatacept [Orencia] • Adalimumab [Humira] • Adalimumab Biosimilars • Apremilast [Otezla] • Baricitinib [Olumiant] • Bimekizumab [Bimzelx] • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Filgotinib [Jyseleca] • Golimumab [Simponi] • Guselkumab [Tremfya] • Infliximab Biosimilars • Ixekizumab [Taltz] • Risankizumab [Skyrizi] • Rituximab [MabThera] • Rituximab Biosimilars • Sarilumab [Kevzara] • Secukinumab [Cosentyx] • Tocilizumab [Ro Actemra] • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] • Ustekinumab [Stelara] | |
| Answer To Question 1: • Abatacept [Orencia] = 49 • Adalimumab [Humira] = 25 • Adalimumab Biosimilars = 310 • Apremilast [Otezla] = 9 • Baricitinib [Olumiant] = 65 • Bimekizumab [Bimzelx] = 0 • Certolizumab [Cimzia] = 43 • Etanercept [Enbrel] = 12 • Etanercept Biosimilars = 145 • Filgotinib [Jyseleca] = 27 • Golimumab [Simponi] = 20 • Guselkumab [Tremfya] = 13 • Infliximab Biosimilars = Split into two parts: Infliximab [Remicade] = 9 Infliximab Biosimilars = 26 • Ixekizumab [Taltz] = 41 • Risankizumab [Skyrizi] = 0 • Rituximab [MabThera] = 7 • Rituximab Biosimilars = 95 • Sarilumab [Kevzara] = <5 • Secukinumab [Cosentyx] = 19 • Tocilizumab [Ro Actemra] = 46 • Tofacitinib [Xeljanz] = 23 • Upadacitinib [Rinvoq] = 58 • Ustekinumab [Stelara] = 10 | |
| Question Number 2: Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs: • Abatacept [Orencia] • Adalimumab [Humira] • Adalimumab Biosimilars • Apremilast [Otezla] • Bimekizumab [Bimzelx] • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Golimumab [Simponi] • Guselkumab [Tremfya] • Infliximab [Remicade] • Infliximab Biosimilars • Ixekizumab [Taltz] • Risankizumab [Skyrizi] • Secukinumab [Cosentyx] • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] • Ustekinumab [Stelara] | |
| Answer To Question 2: • Abatacept [Orencia] = 0 • Adalimumab [Humira] = <5 • Adalimumab Biosimilars = 82 • Apremilast [Otezla] = 9 • Bimekizumab [Bimzelx] = 0 • Certolizumab [Cimzia] = 14 • Etanercept [Enbrel] = <5 • Etanercept Biosimilars = 29 • Golimumab [Simponi] = 7 • Guselkumab [Tremfya] = 13 • Infliximab [Remicade] = <5 • Infliximab Biosimilars = <5 • Ixekizumab [Taltz] = 40 • Risankizumab [Skyrizi] = 0 • Secukinumab [Cosentyx] = 8 • Tofacitinib [Xeljanz] = 17 • Upadacitinib [Rinvoq] = 7 • Ustekinumab [Stelara] = <5 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
